'Why we do What we do in Cardiology'

Tricuspid Regurgitation: TEER for severe TR (Triluminate Pivotal Trial)


Listen Later

Key Points of the Study:

T-TEER with the TriClip device significantly improved health status in patients with severe tricuspid regurgitation (TR) compared to medical therapy alone.

This improvement was seen in both the short-term (1 month) and long-term (1 year) after the procedure.

T-TEER patients were more likely to be alive and well (defined as good KCCQ score and no decline) at 1 year compared to those on medical therapy.

The benefit of T-TEER was greater for patients with lower baseline health scores (KCCQ).

The health status improvement after T-TEER was likely due to reduced TR and correlated with reduced mortality and heart failure hospitalizations.

In conclusion, T-TEER is a promising treatment for severe TR, leading to significant and sustained improvement in health status and quality of life for patients.


Link to article:

https://doi.org/10.1016/j.jacc.2023.10.008

...more
View all episodesView all episodes
Download on the App Store

'Why we do What we do in Cardiology'By Bishnu Subedi


More shows like 'Why we do What we do in Cardiology'

View all
This Week in Cardiology by Medscape

This Week in Cardiology

885 Listeners

Core IM | Internal Medicine Podcast by Core IM Team

Core IM | Internal Medicine Podcast

1,153 Listeners